- Price Target Set at $32: Analyst Andrew Fein from H.C. Wainwright suggests a potential increase of approximately 45.62% from its current price.
- Court Upholds NUPLAZID Patent: The U.S. District Court for the District of Delaware’s decision protects NUPLAZID from generic competition until 2038.
- Market Position Strengthened: Following the court ruling, analysts have adjusted their price targets for ACADIA Pharmaceuticals, reflecting increased confidence in the company’s market position.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company focused on developing and commercializing innovative medicines to address unmet medical needs in central nervous system disorders. One of its key products is NUPLAZID, a treatment for Parkinson’s Disease Psychosis. The company competes with other pharmaceutical firms like Aurobindo Pharma in the generic drug market.
On May 19, 2025, Andrew Fein from H.C. Wainwright set a price target of $32 for ACAD, suggesting a potential increase of approximately 45.62% from its then-current price of $21.98. This optimistic outlook aligns with recent positive developments for ACAD, including a significant 26.5% rise in its stock price to $22.26, as highlighted by a favorable court ruling.
The U.S. District Court for the District of Delaware upheld the validity of Acadia’s ‘721 formulation patent for NUPLAZID, protecting it from generic competition until 2038. This decision blocks challenges from companies like Aurobindo Pharma, ensuring the 34 mg capsule formulation remains exclusive. Catherine Owen Adams, CEO of Acadia, expressed satisfaction with the ruling, emphasizing its importance for the company’s future.
Following the court’s decision, analysts have adjusted their price targets for ACADIA Pharmaceuticals, reflecting increased confidence in the company’s market position. Despite a slight decrease of 0.90% in the stock price to $22.06, the ruling strengthens Acadia’s commitment to advancing therapies for conditions with significant unmet needs.
ACAD’s stock has fluctuated between $21.645 and $22.435 today, with a market capitalization of approximately $3.69 billion. Over the past year, the stock has seen a high of $25.23 and a low of $13.4. With a trading volume of 1,271,107 shares, ACAD remains a key player in the biopharmaceutical industry.
